In a setback for companies such as Zydus and Lupin selling the Mybetriq generic, a US District Court has rejected the arguments made by generic firms regarding the interpretation of the ‘189 patent related to Astellas’ overactive bladder drug, Myrbetriq. Generic players had urged the court to adopt the same interpretation for the term “reduced